Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Complement factor D (Homo sapiens (Human)) | BDBM441981 (1-(2-((2S,4R)-2- (6-chloropyridin- 2-ylcarbamoyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303010 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303024 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303052 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443482 ((2S,4R)-1-(2-(3- acetyl-5- (pyridin-3- ylamino)-1H...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443486 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443487 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443490 (5-((6- chloropyridazin- 3-yl)amino)-1-(2- ((3S,4R)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303012 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303028 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443478 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302880 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302881 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302889 (1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302928 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302930 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303037 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303038 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303040 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303041 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303058 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303059 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443477 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443480 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443488 ((2S,4R)-1-(2-(3- acetyl-5- (pyridin-3- ylamino)-1H...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302874 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303009 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303011 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303013 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443453 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302867 ((2S,4R)-1-(2-(3- acetyl-6- (trifluoromethylsulfon-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302878 ((2S,4R)-1-(2-(3- acetyl-5-(5- fluoropyridin-3- yla...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302882 (1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM442802 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443483 ((2S,4R)-1-(2-(3- acetyl-5- (pyridin-3- ylamino)-1H...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303026 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303057 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443471 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443485 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302883 (1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443495 ((1R,3S,5R)-2-(2- (3-acetyl-5-((5- fluoropyridin-3-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303030 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303039 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303051 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303053 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443470 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443481 ((2S,4R)-1-(2-(3- acetyl-5-(2-(2- methoxyethoxy) py...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443484 ((2S,4R)-1-(2-(3- acetyl-5- (pyridin-3- ylamino)-1H...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443489 ((2S,4R)-1-(2- (3-acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302872 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302874 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302893 (1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302900 (1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302931 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303015 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303042 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303054 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303060 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443493 ((2S,4R)-1-(2-(3- acetyl-5-((2- methylpyrimidin- 5-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443494 ((2S,4R)-1-(2-(3- acetyl-5-((5- yl)amino)-1H- indaz...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303035 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443474 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443457 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303025 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302902 (((3-acetyl-1-(2- ((2S,4R)-2-(2'-chloro- 2-fluorobi...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302863 ((2S,4R)-1-(2-(N-(3- acetyl-1-(2-((2S,4R)- 2-(3-chl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303044 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443476 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303046 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443475 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303032 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443472 ((2S 4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM442000 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303031 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303048 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303049 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302903 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM302945 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303029 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303050 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303023 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443479 ((2S,4R)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303036 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443492 ((S)-1-(2-(3- acetyl-5- (pyrimidin-5- ylamino)-1H- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM443491 ((S)-1-(2-(3- acetyl-5- (pyridin-3- ylamino)-1H- in...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303055 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303045 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303027 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303034 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Complement factor D (Homo sapiens (Human)) | BDBM303056 ((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Achillion Pharmaceuticals, Inc. US Patent | Assay Description Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce... | US Patent US10660876 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
